Skip to content
Peptide research

Leuphasyl

Also known as Pentapeptide-18
Category
Skin & Cosmetic
Administration routes
Topical
Regulatory status
Cosmetic ingredient

What it is

A synthetic pentapeptide applied topically, marketed as a needle-free complement to Botox that eases facial muscle contractions to soften expression lines. Human evidence is limited: a small uncontrolled 20-person study reported wrinkle improvement, and combination-formulation studies cannot isolate the peptide's effect. Safety data is limited, though risks so far seem mild. It is a cosmetic ingredient, not an FDA-approved drug.

Read Full record

Studied uses & evidence

Studied uses(5)

  • Reduction in expression wrinkle depth (manufacturer claims up to 47% combined with Argireline)

    Speculative

    Manufacturer's 47% figure is unpublished in-house data, not a peer-reviewed clinical trial.

  • Modulation of neurotransmitter release to reduce muscle micro-contractions

    Speculative

    Proposed mechanism relies on general enkephalin pharmacology, not tested directly on skin or muscle.

  • Synergistic anti-wrinkle effect when combined with Argireline (Hexapeptide-8)

    Speculative

    No published combination study, synergy claim rests on mechanism reasoning and manufacturer material.

Evidence limits

Evidence Level
Limited Evidence (Cosmetic Industry Data, Minimal Independent Clinical Trials)

The clinical evidence for Leuphasyl consists primarily of proprietary manufacturer studies from Lipotec and cosmetic formulation research. Independent peer-reviewed clinical trials are minimal. A 2026 computational study (PMID 41722287) provided academic validation of its molecular interactions with anti-aging targets, but this was in-silico/in-vitro only. The peptide is widely used in the cosmetics industry based on mechanistic plausibility and manufacturer efficacy claims rather than rigorous clinical trials.

Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)

Cautions & risk summary

General cautions

  • Pregnancy or breastfeeding

    Absolute

    No human reproductive safety data exists for this peptide. Effects on fetal development are unknown.

  • Children under 18

    Absolute

    No pediatric safety data. Not recommended for use in minors.

  • Known hypersensitivity

    Absolute

    Discontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).

Risk summary(2)

Risks = level of concern: High · Moderate · Low · Theoretical

  • Skin irritation or allergic reaction (rare)

    Low
  • Limited independent safety data

    Moderate
Safety & interactions in Full record

Further reading

Read Full record

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.